Cover image not available

Costing statement : Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Alternative Title Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and clinical Excellence
Publication date 0000
Publication location London

Topics

Breast :: Cancer :: Chemotherapy :: England :: Cost effectiveness
England

Catalogue Data

OBNB ID GBB586060
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99449061

ISBD

P1053 1 online resource (2 pages)
P1042 Includes bibliographical reference.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer by National Institute for Health and Clinical Excellence. Published by National Institute for Health and clinical Excellence. Publication and catalogue information, links to buy online and reader comments.